Back to search results

Pharmacogenetics of Response to Semaglutide in Amish Adults

This study is looking at how your genes might affect how your body responds to semaglutide (Ozempic), a medication used for obesity. Researchers want to understand why some people respond better than others to this drug. You would receive semaglutide injections for six weeks. The study will measure changes in how your body handles sugar (insulin secretion and glucose disappearance) both before and after taking the medication. They are specifically looking for genetic differences in healthy adults from the Old Order Amish community in Lancaster County, PA, who are overweight or obese. The study is currently unclear on its recruitment status.

Study design
This is an interventional study planning to enroll 600 participants. It is not specified if it is randomized or blinded.
What's involved
You would receive semaglutide injections for six weeks. You will also undergo two frequently sampled intravenous glucose tolerance tests (FSIGT) and have measurements taken at two clinic visits.
Compensation
Not stated in the trial record.
Follow-up
Your insulin secretion and glucose disappearance will be measured at baseline and after completing 6 weeks of semaglutide therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05071898

Pharmacogenetics of Response to GLP1R Agonists

Recruiting
PHASE1Ages 18–89InterventionalBasic science
University of Maryland, Baltimore
~600 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:Semaglutide Pen Injector [Ozempic]

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
First phase insulin secretion
Measured over Measured both at baseline and after completing 6 weeks of semaglutide therapy
+2 more outcomes measured

Conditions

Obesity
Diabetes Type 2

Explore related trials

Obesity

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Amber L Beitelshees, PharmD · PRINCIPAL_INVESTIGATOR · University of Maryland, Baltimore

Who to contact

Amber L Beitelshees, PharmD
[email protected]
(410)706-0118
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

BMI greater than or equal to 27 kg/m2
Of Amish Descent

Exclusion

Woman of childbearing age who is sexually active
History of diabetes (HbA1c \> 6.5% or random glucose \>200 mg/dL)
Known allergy to semaglutide
Medical issues, which in the judgment of the research physician or PIs might increase the risk associated with participation in the study
eGFR \< 60 mL/min/1.73 sq. m.
Hematocrit \< 35%
TSH \< 0.4 o4 \> 5.5
AST or ALT in excess of 2X the upper limit of normal
Unable to discontinue a drug, vitamin, or nutritional supplement, which in the judgment of the research physician or PIs might alter the response to semaglutide
Personal or family history of medullary carcinoma of the thyroid or multiple endocrine neoplasia, type 2

What this trial measures

  • First phase insulin secretionMeasured both at baseline and after completing 6 weeks of semaglutide therapy

    Area under the curve for plasma insulin levels measured at times between 0-10 min after administration of intravenous glucose (0.3 g/kg)

  • Second phase insulin secretionMeasured both at baseline and after completing 6 weeks of semaglutide therapy

    Area under the curve for plasma insulin levels measured at times between 10-50 min after administration of intravenous glucose (0.3 g/kg)

  • Rate of glucose disappearanceMeasured both at baseline and after completing 6 weeks of semaglutide therapy

    Slope of the plot of log(glucose concentration) as a function of time. This will be calculated based on a linear regression using data points between 25-50 minutes after administration of intravenous glucose (0.3 g/kg)